Effect of weight loss on serum osteocalcin and its association with serum adipokines

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Albadah, Mohammed S ^a,b   Dekhil, Hafedh ^a   Shaik, Shaffi Ahamed ^a   Alsaif, Mohammed A ^a,c   Shogair, Mustafa ^a   Nawaz, Shahid ^a   Alfadda, Assim A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; C REACTIVE PROTEIN; CHEMERIN; CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; RESISTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNDERCARBOXYLATED OSTEOCALCIN; VITAMIN D;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; DIET THERAPY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84924240986     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/508532     Document Type: Article

References (45)

1. T. Temelkova-Kurktschiev and T. Stefanov, "Lifestyle and genetics in obesity and type 2 diabetes," Experimental and Clinical Endocrinology & Diabetes, vol. 120, no. 1, pp. 1-6, 2012.
2. P. Hossain, B. Kawar, andM. El Nahas, "Obesity and diabetes in the developing world-a growing challenge," The New England Journal of Medicine, vol. 356, no. 3, pp. 213-215, 2007.
3. H. E. Lebovitz and M. A. Banerji, "Point: visceral adiposity is causally related to insulin resistance," Diabetes Care, vol. 28, no. 9, pp. 2322-2325, 2005.
4. E. E. Kershaw and J. S. Flier, "Adipose tissue as an endocrine organ," Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548-2556, 2004.
5. G. R. Hajer, T. W. van Haeften, and F. L. J. Visseren, "Adipose tissue dysfunction in obesity, diabetes, and vascular diseases," European Heart Journal, vol. 29, no. 24, pp. 2959-2971, 2008.
6. M. Blüher, "Adipose tissue dysfunction in obesity," Experimental and Clinical Endocrinology & Diabetes, vol. 117, no. 6, pp. 241-250, 2009.
7. P. S. Hinton, J. D. LeCheminant, B. K. Smith, R. S. Rector, and J. E. Donnelly, "Weight loss-induced alterations in serummarkers of bone turnover persist during weight maintenance in obese men and women," Journal of the American College of Nutrition, vol. 28, no. 5, pp. 565-573, 2009.
8. L. Fontana, "Calorie restriction and cardiometabolic health," European Journal of Cardiovascular Prevention and Rehabilitation, vol. 15, no. 1, pp. 3-9, 2008.
9. M. Gnacínska, S. Ma?gorzewicz, M. Stojek, W. ?ysiak-Szyd?owska, and K. Sworczak, "Role of adipokines in complications related to obesity: a review," Advances in Medical Sciences, vol. 54, no. 2, pp. 150-157, 2009.
10. F. Ziemke and C. S. Mantzoros, "Adiponectin in insulin resistance: lessons from translational research," The American Journal of Clinical Nutrition, vol. 91, no. 1, pp. 258S-261S, 2010.
11. A. A. Alfadda, "Circulating adipokines in healthy versus unhealthy overweight and obese subjects," International Journal of Endocrinology, vol. 2014,Article ID 170434, 7 pages, 2014.
12. S. Fukumoto and T. J. Martin, "Bone as an endocrine organ," Trends in Endocrinology andMetabolism, vol. 20, no. 5, pp. 230-236, 2009.
13. N. K. Lee and G. Karsenty, "Reciprocal regulation of bone and energy metabolism," Journal of Musculoskeletal Neuronal Interactions, vol. 8, no. 4, p. 351, 2008.
14. A. L. Gould,G. M. Davies, E. Alemao,D. D. Yin, and J. R. Cook, "Cholesterol reduction yields clinical benefits: meta-analysis including recent trials," Clinical Therapeutics, vol. 29, no. 5, pp. 778-794, 2007.
15. N. K. Lee, H. Sowa, E. Hinoi et al. , "Endocrine regulation of energy metabolism by the skeleton," Cell, vol. 130, no. 3,pp. 456-469, 2007.
16. C. B. Confavreux, R. L. Levine, and G. Karsenty, "A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms," Molecular and Cellular Endocrinology, vol. 310, no. 1-2, pp. 21-29, 2009.
17. K. S. Gravenstein, J. K. Napora, R. G. Short et al. , "Crosssectional evidence of a signaling pathway frombone homeostasis to glucose metabolism,"TheJournal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. E884-E890, 2011.
18. I. Kanazawa, T. Yamaguchi, M. Yamauchi et al. , "Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus," Osteoporosis International, vol. 22, no. 1, pp. 187-194, 2011.
19. Y.-C. Hwang, I.-K. Jeong, K.-J. Ahn, and H.-Y. Chung, "Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level," Osteoporosis International, vol. 23, no. 4, pp. 1337-1342, 2012.
20. N. Abseyi, Z. Şiklar, M. Berbero?glu, B. Hac?hamdio?glu, Ş. S. Erdeve, and G. Ocąl, "Relationships between osteocalcin, glucose metabolism, and adiponectin in obese children: is there crosstalk between bone tissue and glucose metabolism?" Journal of Clinical Research in Pediatric Endocrinology, vol. 4, no. 4, pp. 182-188, 2012.
21. S. D. Vasikaran, "Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis," CriticalReviews inClinical Laboratory Sciences, vol. 45, no. 2, pp. 221-258, 2008.
22. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge," Clinical Chemistry, vol. 18, no. 6, pp. 499-502, 1972.
23. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man," Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
24. A. Fisher, W. Srikusalanukul, M. Davis, and P. Smith, "Interactions between serum adipokines and osteocalcin in older patients with hip fracture," International Journal of Endocrinology, vol. 2012,Article ID 684323, 11 pages, 2012.
25. J. Bacchetta, S. Boutroy, F. Guebre-Egziabher et al. , "The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease," Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3120-3125, 2009.
26. I. Kanazawa, T. Yamaguchi, Y. Tada, M. Yamauchi, S. Yano, and T. Sugimoto, "Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes," Bone, vol. 48, no. 4, pp. 720-725, 2011.
27. A. G. Pittas, S. S. Harris,M. Eliades, P. Stark, and B. Dawson-Hughes, "Association between serum osteocalcin and markers of metabolic phenotype," Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 3, pp. 827-832, 2009.
28. A. Prats-Puig, M. Mas-Parareda, E. Riera-Pérez et al. , "Carboxylation of osteocalcin affects its association with metabolic parameters in healthy children," Diabetes Care, vol. 33, no. 3, pp. 661-663, 2010.
29. T. Tamura, M. Yoneda, K. Yamane et al. , "Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus," Metabolism: Clinical and Experimental, vol. 56, no. 5, pp. 623-628, 2007.
30. B. Buday, E. Kulcsar, B. Literati Nagy et al. , "The role of osteocalcin in the connection of bone and glucose metabolism in humans," OrvosiHetilap, vol. 149, no. 52, pp. 2453-2461, 2008.
31. B. Bozic, G. Loncar, N. Prodanovic et al. , "Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure," Journal of Cardiac Failure, vol. 16, no. 4, pp. 301-307, 2010.
32. Y.-C. Hwang, K. J. Ahn, J.-H. Jee, H. Y. Chung, I.-K. Jeong, and M.-K. Lee, "Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8. 4-year retrospective follow-up study," Diabetes Care, vol. 35, no. 9, pp. 1919-1924, 2012.
33. C. M. Steppan and M. A. Lazar, "The current biology of resistin," Journal of Internal Medicine, vol. 255, no. 4, pp. 439-447, 2004.
34. A. Fisher, E. Southcott, R. Li,W. Srikusalanukul, M. Davis, and P. Smith, "Serum resistin in older patients with hip fracture: relationship with comorbidity and biochemical determinants of bone metabolism," Cytokine, vol. 56, no. 2, pp. 157-166, 2011.
35. S. Muruganandan and C. J. Sinal, "The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation," IUBMB Life, vol. 66, no. 3, pp. 147-155, 2014.
36. S. Muruganandan, H. J. Dranse, J. L. Rourke, N. M. Mcmullen, and C. J. Sinal, "Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis," StemCells, vol. 31,no. 10, pp. 2172-2182, 2013.
37. S. Muruganandan, A. A. Roman, and C. J. Sinal, "Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bonemarrow stemcells," Journal of Bone andMineral Research, vol. 25, no. 2, pp. 222-234, 2010.
38. I. Levinger, G. Jerums, N. K. Stepto et al. , "The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obesemen," Journal of Bone andMineral Research, vol. 29, no. 12, pp. 2571-2576, 2014.
39. P. Garnero, "New developments in biological markers of bone metabolism in osteoporosis," Bone, vol. 66, pp. 46-55, 2014.
40. U. Saleem, T. H. Mosley, and I. J. Kullo, "Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 7, pp. 1474-1478, 2010.
41. A. Tan, Y. Gao, X. Yang et al. , "Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey," Metabolism: Clinical and Experimental, vol. 60, no. 8, pp. 1186-1192, 2011.
42. B. B. Yeap, S. A. P. Chubb, L. Flicker et al. , "Reduced serum total osteocalcin is associated withmetabolic syndrome in oldermen via waist circumference, hyperglycemia, and triglyceride levels," European Journal of Endocrinology, vol. 163, no. 2, pp. 265-272, 2010.
43. A. A. Alfadda,A. Masood, S. A. Shaik,H. Dekhil, andM. Goran, "Association between osteocalcin, metabolic syndrome, and cardiovascular risk factors: role of total and undercarboxylated osteocalcin in patients with type 2 diabetes," International Journal of Endocrinology, vol. 2013, Article ID 197519, 6 pages, 2013.
44. B. B. Yeap, S. A. P. Chubb, L. Flicker et al. , "Associations of total osteocalcin with all-cause and cardiovascularmortality in older men. The Health inMen Study," Osteoporosis International, vol. 23, no. 2, pp. 599-606, 2012.
45. K. Holvik, N. M. van Schoor, E. M. W. Eekhoff et al. , "Plasma osteocalcin levels as a predictor of cardiovascular disease in older men and women: a population-based cohort study," European Journal of Endocrinology, vol. 171, no. 2, pp. 161-170, 2014.